Skip to main content
padlock icon - secure page this page is secure

BACE Inhibitors as Potential Therapeutics for Alzheimer's disease

Buy Article:

$68.00 + tax (Refund Policy)

Accumulation of Aβ peptide in the brain results in the formation of amyloid plaques characteristic of Alzheimer's disease (AD) pathology. Aβ soluble oligomers and protofibrils are neurotoxic and these are believed to be a major cause of neurodegeneration in AD. Aβ is derived from a precursor protein by two sequential cleavage steps involving β- and γ-secretases, two proteolytic enzymes that represent rational drug targets. β-secretase was identified as the membrane-anchored aspartyl protease BACE (or BACE1) and found to be elevated in brain cortex of patients with sporadic Alzheimer's disease. In this review, we summarize current approaches towards the development of BACE inhibitors with focus on bioactive compounds and related patents. Recent reports have described drugs that are effective at inhibiting Aβ production in the brain of transgenic mouse models. The beginning of Phase I clinical trials has been approved for one of them and we can expect that in the near future BACE inhibitors will provide novel effective therapeutics to treat AD.

No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Alzheimer's disease; Aβ amyloid; BACE1; aspartyl protease; inhibitors; β-secretase

Document Type: Research Article

Publication date: November 1, 2007

More about this publication?
  • Recent Patents on CNS Drug Discovery publishes review articles on recent patents in the field of CNS drug discovery e.g. novel bioactive compounds, analogs & targets. A selection of important and recent patents on CNS drug discovery is also included in the journal. The journal is essential reading for all researchers involved in CNS drug design and discovery.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more